银屑病患者接受肿瘤坏死因子抑制剂治疗的感染风险:一项为期20年的随机对照试验系统综述与荟萃分析
该系统综述与荟萃分析纳入48项双盲随机对照试验、共15464例银屑病或银屑病关节炎患者,评估肿瘤坏死因子抑制剂(TNFis)的感染风险。结果显示TNFis组总体感染风险轻度升高(RR=1.09,95%CI 1.02-1.15),但严重感染、上呼吸道感染和鼻咽炎风险未显著增加。亚组分析中仅依那西普与总体感染风险升高相关,赛妥珠单抗与上呼吸道感染风险升高相关。
要点
- TNFis组总体感染风险轻度升高(RR=1.09,95%CI 1.02-1.15)。
- 严重感染风险未显著增加(RR=0.95,95%CI 0.61-1.49)。
- 上呼吸道感染和鼻咽炎风险未显著增加。
核心结论
- 现有证据提示银屑病患者接受TNFis治疗时总体感染风险轻度升高但一般可耐受,严重感染、上呼吸道感染或鼻咽炎风险未见增加。
研究设计与样本
- 系统检索Medline(PubMed)、Cochrane对照试验中心注册库(CENTRAL)、EMBASE和ClinicalTrials.gov数据库,从建库至2021年12月31日,纳入比较TNFis或其他生物制剂与安慰剂的双盲随机对照试验,共48项研究、15464例银屑病或银屑病关节炎成人患者。
主要发现
- TNFis组总体感染风险轻度升高(RR=1.09,95%CI 1.02-1.15)。
- TNFis组严重感染风险未显著增加(RR=0.95,95%CI 0.61-1.49)。
- TNFis组上呼吸道感染风险未显著增加(RR=1.10,95%CI 0.94-1.28)。
- TNFis组鼻咽炎风险未显著增加(RR=1.14,95%CI 1.00-1.30)。
- 固定效应模型亚组分析中,依那西普与总体感染风险升高相关(RR=1.14,95%CI 1.03-1.27),赛妥珠单抗与上呼吸道感染风险升高相关(RR=1.42,95%CI 1.02-1.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumour necrosis factor inhibitors (TNFis) are commonly used for treating psoriatic diseases; however, the risk of infection while receiving TNFis remains uncertain. The aim of this study was to investigate the infection risk in patients with psoriatic disease receiving TNFis. A prospectively registered systematic literature search was conducted in Medline (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and the ClinicalTrials.gov databases from inception to December 31, 2021. We included double-blind randomized controlled trials that compared TNFis or other biologics with placebo in adults with psoriasis or psoriatic arthritis. The primary outcomes included overall and serious infection risks, and secondary outcomes included upper respiratory infections and nasopharyngitis risks. The risk ratio of the dichotomous outcome was calculated using the Mantel-Haenszel method with random effects, and heterogeneity was assessed using Cochran's Q statistic and quantified using the I-squared statistic. A total of 48 studies with 15 464 patients with psoriatic diseases were included. The meta-analysis demonstrated a slightly increased overall infection risk (risk ratio = 1.09; 95% confidence interval, 1.02-1.15) but not serious infection risk (risk ratio = 0.95; 95% confidence interval, 0.61-1.49) among patients receiving TNFis. There were also no increased risks of upper respiratory infections (risk ratio = 1.10; 95% confidence interval, 0.94-1.28) or nasopharyngitis (risk ratio = 1.14; 95% confidence interval, 1.00-1.30). In subgroup analyses using the fixed effects model, only etanercept and certolizumab pegol were, respectively, associated with an increased risk of overall infection (RR = 1.14, 95% CI, 1.03-1.27) and upper respiratory infections (RR = 1.42, 95% CI, 1.02-1.98). In conclusion, evidence to date suggests an increased overall infection risk that is generally tolerable in patients with psoriatic diseases receiving TNFis. There are no increased risks of serious infections, upper respiratory infections or nasopharyngitis.
引用
- Wang YC, Lin YH, Ma SH, et al. Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2022. PMID: 35793472. doi:10.1111/jdv.18407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。